Details for New Drug Application (NDA): 215917

✉ Email this page to a colleague

NDA 215917 describes EDARAVONE, which is a drug marketed by Dr Reddys, Gland Pharma Ltd, Hikma, Long Grove Pharms, and Xgen Pharms, and is included in five NDAs. It is available from four suppliers. Additional details are available on the EDARAVONE profile page.

The generic ingredient in EDARAVONE is edaravone. Five suppliers are listed for this compound. Additional details are available on the edaravone profile page.

Summary for 215917

Tradename:	EDARAVONE
Applicant:	Dr Reddys
Ingredient:	edaravone
Patents:	0

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAVENOUS			Strength	60MG/100ML (0.6MG/ML)
Approval Date:	May 6, 2024	TE:	AP	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.